2,2-DIFLUOROPROPIONAMIDE DERIVATIVE OF BARDOXOLONE METHYL, PHARMACEUTICAL COMPOSITIONS AND POLYMORPHS THEREOF FOR USE IN TREATING CERTAIN CONDITIONS
申请人:Reata Pharmaceuticals, Inc.
公开号:EP3444261A1
公开(公告)日:2019-02-20
The present invention relates to the compound: N-((4aS,6aR,6bS,8aR,12aS,14aR,14bS)-11-cyano-2,2,6a,6b,9,9,12a-heptamethyl-10,14-dioxo-l,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,12a,14,14a,14b-octadecahydropicen-4a-yl)-2,2-difluoropropanamide and polymorphic forms and pharmaceutical compositions thereof for use in the treatment of cancer in combination with immunotherapy, for use in the treatment of conditions associated with oxidative stree caused by mitochondrial dysfunction and for use in the treatment of seizure disorders.
本发明涉及以下化合物:N-((4aS,6aR,6bS,8aR,12aS,14aR,14bS)-11-cyano-2,2,6a,6b,9,9,12a-heptamethyl-10,14-dioxo-l,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,12a,14,14a,14b-octadecahydropicen-4a-yl)-2,2-二氟丙酰胺及其多晶型和药物组合物,用于结合免疫疗法治疗癌症,用于治疗与线粒体功能障碍引起的氧化状态有关的疾病,以及用于治疗癫痫发作性疾病。